


# **Results of a Kidney Transplant Program at a Clinic in the Colombian Caribbean Region – 2019 to 2022**

Henry J. González-Torres<sup>\*12</sup>, Leinad Y. Moran Marin<sup>1</sup>, Gustavo J. Aroca-Martínez<sup>13</sup>, Adriana I. Agamez Diaz<sup>2</sup>, Alex Domínguez Vargas<sup>24</sup>, Omar Cabarcas Barbosa<sup>13</sup>, Sandra Hernández Agudelo<sup>13</sup>

# Background

Kidney transplantation is an effective treatment option and, in many cases, the best option for patients with end-stage renal disease. However, it still faces significant challenges that need to be addressed to improve the quality of life and survival of transplant recipients. Therefore, follow-up programs for these renal patients are essential. Hence, the objective of this study was to evaluate the outcomes of a kidney transplant program in a clinic in the Colombian Caribbean Region between the years 2019 and 2022.



# **Methods**

An analytical cohort study was conducted, with a summary review of the variables, reported in means and standard deviations or medians and interguartile ranges depending on the normality of the variable. On the other hand, categorical described using absolute variables were and relative frequencies. The Student's t-test or Wilcox test was used depending on the normality of the variable. The Kruskal-Wallis test was employed to evaluate the medians obtained by patients Rate (GFR) across four the Glomerular Filtration in measurements. To analyze categorical variables, the exact Fisher test or the Chi-square test was used. A Kaplan-Meier analysis was performed to estimate graft survival according to donor type. A pvalue of <0.05 was considered statistically significant. The R-CRAN software version 4.3.2 was used for statistical analyses.

# **Results:**

Table 1 General characteristics of patients in the kidney transplant program

 
 Table 2 Clinical Profile of Renal Transplant Program Patients by
Gender

program.					
Characteristic	n = 1641	Characteristic	Female	Male	p-value
Gender			(n= 63) <sup>1</sup>	(n= 101) <sup>1</sup>	
Female	63 (38%)	Origin			0.065 <sup>2</sup>
Male	101 (62%)	Extrainstitutional	32 (51%)	66 (65%)	
Origin		Institutional	31 (49%)	35 (35%)	
Extramural	98 (60%)	Comorbidities			
Intramural	66 (40%)	Hypertension	49 (78%)	78 (77%)	>0.9 <sup>2</sup>
Comorbidities				, , , , , , , , , , , , , , , , , , ,	0.040 <sup>3</sup>
Hypertension	127 (77%)	DM1	2 (3.2%)	1 (1.0%)	0.040
DM1	3 (1.8%)	DM2	5 (7.9%)	21 (21%)	3
DM2	26 (16%)	Hyperparathyroidism	9 (14%)	4 (4.0%)	0.033 <sup>3</sup>
Hyperparathyroidism	13 (7.9%)	Primary Renal Disea	0.5 <sup>3</sup>		
Hypothyroidism	7 (4.3%)	NAH	12 (19%)	21 (21%)	
Graft Failure		ND	6 (9.5%)	20 (20%)	
CN	1 (0.6%)	NL	5 (7.9%)	3 (3.0%)	
GEFS	4 (2.4%)	GFR (ml/min/m2)	60 (36, 83)	46 (30, 79)	0.44
GNMP	7 (4.3%)	Donor Type			0.2 <sup>2</sup>
GNM	1 (0.6%)	Deceased	35 (56%)	46 (46%)	
NAH	33 (20%)	Living	28 (44%)	55 (54%)	
No Diagnosis (ND)	26 (16%)	PRA (%) (Panel Reacti		<b>/</b>	0.13 <sup>3</sup>
No Lesions (NL)	8 (4.9%)				0.10
Donor Type		0-10	59 (94%)	100 (99%)	
Deceased	81 (49%)	11-50	2 (3.2%)	1 (1.0%)	
Living	83 (51%)	51-100	2 (3.2%)	0 (0%)	
Graft Loss	14 (8.5%)	Graft Loss	4 (6.3%)	10 (9.9%)	0.4 <sup>2</sup>
Mortality	4 (2.4%)	Mortality	1 (1.6%)	3 (3.0%)	>0.9 <sup>3</sup>

Figure 1 Distribution of comorbidities by sex.

	Tipo de Donante			
Characteristic	Dead	Alive	p-value	
	(n=81)1	(n=83)1		
Gender			0.22	
Female	35 (43%)	28 (34%)		
Male	46 (57%)	55 (66%)		
НТА	66 (81%)	61 (73%)	0.22	
Diabetes			0.33	
DM1	0 (0%)	3 (3.6%)		
DM2	12 (15%)	14 (17%)		
<b>Primary Renal Disease</b>	e		0.43	
NAH	13 (16%)	20 (24%)		
ND	12 (15%)	14 (17%)		
NL	3 (3.7%)	5 (6.0%)		
GFR (ml/min/m2)	52 (5, 95)	59 (6, 134)	0.0204	
Cool Isquemi (h)	12.5 (9.9, 15.0)	7.0 (4.0, 9.5)	< 0.0014	
PRA (%)			>0.93	
0-10	79 (98%)	80 (96%)		
11-50	1 (1.2%)	2 (2.4%)		
51-100	1 (1.2%)	1 (1.2%)		
HLA-A (# Identity)			0.72	
1	14 (67%)	15 (71%)		
2	7 (33%)	6 (29%)		
HLA-B (# Identity)			>0.93	
1	12 (92%)	12 (92%)		
2	1 (7.7%)	1 (7.7%)		
HLA-DR (# Identity)			0.53	
1	21 (95%)	12 (86%)		
2	1 (4.5%)	2 (14%)		
Graft Loss	7 (8.6%)	7 (8.4%)	>0.92	
Mortality	1 (1.2%)	3 (3.6%)	0.63	

time according to donor type.

Table 3 Clinical characteristics of patients in the kidney transplant program according to donor type.

WCN24-AB-1676






Table 4 Glomerular Filtration Rate in Kidney Transplant Program Patients by Donor Type

Tipo de	TFG (m				
Donante	TFG_1	TFG_2	TFG_3	TFG_4	p-value
Dead	51	54	55	52	0.071
Alive	58	60	57	59	0.081
p-value	0.072	0.082	0.252	0.012	NA

## Figure 3 Glomerular Filtration

### Sobrevida del Injerto Renal





Tipo de Donante 📌 Tipo\_Donante=Cadavérico 📌 Tipo\_Donante=Vivo

# Conclusion

The 10-year graft survival was notably higher in patients who received transplants from deceased donors, emphasizing the importance of this source of organs in the transplant program. This indicates that the management of kidney transplants in the Colombian Caribbean Region should be improved and optimized

